GlobeNewsWire
28 Jul 2026, 11:50 UTC · 7w ago
Verdict
Headline takes no side. We score AIFF +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
An FDA Advisory Committee recommended easing compounding restrictions for six peptides, including Epitalon and Semax, to broaden physician access.
More positive than 92% of claims this week
Firefly Neuroscience (AIFF) and Next Health have formed a strategic partnership to integrate AI-powered EEG brain biomarker technology with personalized peptide protocols.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
The initiative aims to replace subjective cognitive assessments with objective, data-driven EEG/ERP brain biomarkers for monitoring cognitive therapies.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company announced a strategic partnership with Next Health to launch a precision cognitive health platform and cited positive FDA Advisory Committee trends.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
+6.8%
Price agrees with the score
$1.26 vs $1.18 close before publication (Jul 27) · not market-adjusted
AIFF chart →
